Aarkstore - Lonsurf (Colorectal Cancer) - Forecast and Market Analysis to 2023
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic. Browse full report @ http://bit.ly/1HiLlHF
This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the colorectal cancer market, with coverage of multiple settings of the disease including neoadjuvant/adjuvant, first-, second-, third-line KRAS wild-type and mutation-positive, and fourth-line metastatic.
Browse full report @ http://bit.ly/1HiLlHF
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>Aarks<strong>to</strong>re</strong> Enterprise<br />
7.2 Abbreviations 44<br />
7.3 Methodology 47<br />
7.4 <strong>Forecast</strong>ing Methodology 47<br />
7.4.1 Diagnosed <strong>Colorectal</strong> <strong>Cancer</strong> Patients 47<br />
7.4.2 Percent Drug-Treated Patients 48<br />
7.4.3 General Pricing Assumptions 48<br />
7.4.4 Average Body Weight <strong>and</strong> Surface Area Across the 8MM 49<br />
7.4.5 Individual Drug Assumptions 50<br />
7.4.6 Generic Erosion 50<br />
7.5 Primary Research - KOLs Interviewed for this Report 51<br />
7.6 Primary Research - Prescriber Survey 53<br />
7.7 About the Authors 54<br />
7.7.1 Analyst 54<br />
7.7.2 Global Head of Healthcare 55<br />
7.8 About GlobalData 56<br />
7.9 Disclaimer 56<br />
List of Tables<br />
Table 1: TNM <strong>and</strong> Staging Classification System for CRC 15<br />
Table 2: Symp<strong>to</strong>ms of <strong>Colorectal</strong> <strong>Cancer</strong> 16<br />
Table 3: Treatment Guidelines for CRC 21<br />
Table 4: Most-Prescribed Neoadjuvant/Adjuvant Regimens for Early-Stage CRC in the Global <strong>Market</strong>s, 2013<br />
22<br />
Table 5: Most Prescribed Targeted Therapies for Metastatic CRC by Segment in the Global <strong>Market</strong>s, 2013 23<br />
Table 6: Leading Treatments for CRC, 2014 32<br />
Table 7: Product Profile - <strong>Lonsurf</strong> 35
Change language